A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Published

Journal Article

Despite palliative treatments, tumor-induced bone disease (TIBD) remains highly debilitating for many cancer patients and progression typically results in death within two years. Therefore, more effective therapies with enhanced anti-resorptive and cytotoxic characteristics are needed. We developed bisphosphonate-chemotherapeutic conjugates designed to bind bone and hydrolyze, releasing both compounds, thereby targeting both osteoclasts and tumor cells. This study examined the effects of our lead compound, MBC-11 (the anhydride formed between arabinocytidine (AraC)-5'-phosphate and etidronate), on bone tumor burden, bone volume, femur bone mineral density (BMD), and overall survival using two distinct mouse models of TIBD, the 4T1/luc breast cancer and the KAS-6/1-MIP1alpha multiple myeloma models. In mice orthotopically inoculated with 4T1/luc mouse mammary cells, MBC-11 (0.04 microg/day; s.c.) reduced the incidence of bone metastases to 40% (4/10), compared to 90% (9/10; p=0.057) and 100% (5/5; p=0.04) of PBS- or similarly-dosed, zoledronate-treated mice, respectively. MBC-11 also significantly decreased bone tumor burden compared to PBS- or zoledronate-treated mice (p=0.021, p=0.017, respectively). MBC-11 and zoledronate (0.04 microg/day) significantly increased bone volume by two- and four-fold, respectively, compared to PBS-treated mice (p=0.005, p<0.001, respectively). In mice systemically injected with human multiple myeloma KAS-6/1-MIP1alpha cells, 0.04 and 4.0 microg/day MBC-11 improved femur BMD by 13% and 16%, respectively, compared to PBS (p=0.025, p=0.017, respectively) at 10 weeks post-tumor cell injection and increased mean survival to 95 days compared to 77 days in mice treated with PBS (p=0.047). Similar doses of zoledronate also improved femur BMD (p< or =0.01 vs PBS) and increased mean survival to 86 days, but this was not significantly different than in PBS-treated mice (p=0.53). These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for TIBD.

Full Text

Duke Authors

Cited Authors

  • Reinholz, MM; Zinnen, SP; Dueck, AC; Dingli, D; Reinholz, GG; Jonart, LA; Kitzmann, KA; Bruzek, AK; Negron, V; Abdalla, AK; Arendt, BK; Croatt, AJ; Sanchez-Perez, L; Sebesta, DP; Lönnberg, H; Yoneda, T; Nath, KA; Jelinek, DF; Russell, SJ; Ingle, JN; Spelsberg, TC; Dixon, HBFH; Karpeisky, A; Lingle, WL

Published Date

  • July 2010

Published In

Volume / Issue

  • 47 / 1

Start / End Page

  • 12 - 22

PubMed ID

  • 20233612

Pubmed Central ID

  • 20233612

Electronic International Standard Serial Number (EISSN)

  • 1873-2763

International Standard Serial Number (ISSN)

  • 8756-3282

Digital Object Identifier (DOI)

  • 10.1016/j.bone.2010.03.006

Language

  • eng